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Aqueous solubility of a drug substance is an important attribute affecting oral bioavailability. 
Nanonization, particle size reduction to submicron level, is an elegant approach to improve 
drug solubility and dissolution by increasing the surface energy, which in turn necessitates the 
use of stabilizers. The purpose of this study was to develop a nanosuspension of a practically 
water-insoluble investigational molecule by nanomilling approach using wet media milling. A 
variety of polymeric and surface active excipients were tested for their wettability. A 
combination of hydroxypropyl methylcellulose and sodium lauryl sulfate (SLS) were selected 
as stabilizers on the bases of compatibility studies and efficient wettability behaviour in 
contact angle measurements (≈80˚). A factorial design set-up was used to study the effect of 
milling bead diameter and stabilizer concentration on the efficiency of particle size reduction. 
Nanonization outcome was different when milling beads of 0.5 mm and 1 mm diameter were 
used at different concentrations of the stabilizers, which demonstrated the complex nature of 
the whole system. Storage of the nanosuspensions under different temperature conditions 
resulted only in minor changes of the particle size fractions.  
 







Development of nanosized pure drug crystals (nanonization) is one of the approaches to 
improve dissolution behaviour of poorly water-soluble drugs and it has made the fastest 
breakthrough from development to an industrial scale (Medarevic et al., 2018). 
Nanosuspensions are considered as sub-micron (usually 200–500 nm) colloidal suspensions 
of drug particles, which are stabilized by surfactants, polymers or the mixture of the both (Liu 
et al., 2011; Malamatari et al., 2018; Medarevic et al., 2018). The basic idea behind this 
approach is that particle size reduction leads to increased drug dissolution rate as well as 
increased saturated solubility of the poorly soluble drugs (Medarevic et al., 2018; Oktay et al., 
2018). According to Noyes-Whitney equation, dissolution rate is increased due to the higher 
interfacial area that is associated to decreased particle size. The increase in saturation 
solubility is explained by the Ostwald-Freundlich theory, which suggests that this happens 
due to particle size being reduced to approximately smaller than 1 μm. Apart from these 
advantages, nanosuspensions have many other benefits: a high drug loading, low incidence of 
side effects, low cost, better adhesion to biological membranes, potential of targeted drug 
delivery, reduced fed/fasted state variability, possibility of many administration routes etc. 
(Liu et al., 2011; Liu et al., 2015; Medarevic et al., 2018). 
It is well established that nanosuspensions are associated witphysical instability (Azad et al., 
2016; Knieke et al., 2013; Patel et al., 2018). This is due to the high interfacial free energy, 
which is associated with their large interfacial area (Malamatari et al., 2018; Wang et al., 
2013). Particle agglomeration and crystal growth can result in losing many important 
properties of nanosuspensions; therefore, stability must be ensured during the milling process 
as well as during the subsequent storage (Azad et al., 2016; Knieke et al., 2013; Wang et al., 
2013). This is achieved by either steric or electrostatic stabilization, provided by various ionic 
and non-ionic stabilizers, which are therefore a necessary component of nanosuspensions 
(Knieke et al., 2013; Malamatari et al., 2018). In fact, the right choice of stabilizers is one of 
the most important factors for both physical stability as well as in achieving the target particle 
size (Peltonen and Hirvonen, 2010). The most commonly used stabilizers that have been 
reported are different kinds of polymers, such as poloxamers, polyvinyl pyrrolidone (PVP), 
cellulose derivates (e.g. hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose 
(HPMC), hydroxyethyl cellulose (HEC), methylcellulose (MC)), and vitamin E TPGS, acting 
mainly via steric stabilization. Also surfactants, either ionic like sodium lauryl sulphate (SLS) 
providing electrostatic stabilization or non-ionic like polysorbates stabilizing sterically, are 
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widely utilized (Peltonen and Hirvonen, 2018; Tuomela et al., 2016; Wang et al., 2013). A 
common way to achieve stability is also the combination of both steric and electrostatic 
stabilizers, which is suggested to give a synergistic stabilizing effect, usually referred to as 
electrosteric stabilization (Malamatari et al., 2018).  
Nanosuspensions can be produced via reduction of particle size (top-down techniques) or via 
precipitation of dissolved molecules into solid particles (bottom-up techniques) (Ghosh et al., 
2011; Liu et al., 2011; Oktay et al., 2018). By far the most typical and widely used top-down 
approach is wet-ball milling, also referred to as wet milling (Möschwitzer, 2013). This 
technique employs a certain grinding medium to mill the microcrystalline aqueous suspension 
into nanosuspension (Chin et al., 2014). During the process, high energy and shear forces are 
generated due to the stirring of drug particles, aqueous solution of stabilizers and milling 
media (beads/pearls, often yttrium stabilized zirconium oxide) at high speed, which provide 
the energy necessary for particle breakage and, thus, formation of nanosized particles (Afolabi 
et al., 2014; Peltonen, 2018; Peltonen and Hirvonen, 2010). Wet milling has many benefits, 
which makes it such a widely used technique; it is rather simple, it avoids organic solvents, it 
is easy to change or scale-up, the process repeatability is very high, it is cost-efficient etc. (Liu 
et al., 2011; Möschwitzer, 2013; Peltonen and Hirvonen, 2010, 2018). However, there are 
several parameters affecting the efficiency of achieving optimal particle size reduction, such 
as drug amount, quantity and size of the milling beads, milling speed, milling time and 
temperature (Möschwitzer, 2013). Milling beads have been found to be a crucial and complex 
parameter in achieving optimal particle size in different studies (Ghosh et al., 2011; Ghosh et 
al., 2013; Ghosh et al., 2012). Commonly milling beads, which are used to produce 
nanocrystals, are 0.5 mm and 1 mm in diameter. Milling beads larger than 1 mm in diameter 
are not very efficient in producing nanocrystals. On the other hand, beads smaller than 0.5 
mm are too small to generate sufficient kinetic energy for production of nanocrystals, which 
are smaller than what is achievable using 0.5 mm beads (Kakran et al., 2012; Medarevic et al., 
2018; Toziopoulou et al., 2017).  
As stated above, there is an interplay between many variables which affect particle size and 
stability of nanosuspensions, and the importance of each of them is challenging to evaluate. In 
previous studies, attempts have been made to estimate the influence of different parameters on 
the formation of nanosuspensions using different approaches (e.g. Design of Experiment, 
dynamic equilibrium curve etc.) (Ghosh et al., 2013; Nekkanti et al., 2015; Oktay et al., 
2018). However, it is still not possible to predict an optimal stabilizer type and concentration 
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for a given drug that ensures an effective particle size reduction and proper stability. 
Furthermore, it is still unclear, how different bead sizes influence particle size in relation to 
different stabilizer concentrations and amounts of drug in the milling vessel, where both the 
parameters are affecting the viscosity of the system.  
The primary aim of our study was to gain an insight into how two different bead sizes in the 
wet-ball milling process affect particle sizes when different viscosity affecting stabilizer 
concentrations are used; particularly of interest was how smaller beads perform in highly 
viscous media compared to larger beads. Our secondary aim was to investigate the stability of 
prepared nanosuspensions in different storage conditions. Nanosuspensions were prepared by 
wet-ball milling using two different bead sizes; 0.5 mm and 1.0 mm. For both the bead sizes, 
several combinations of different concentrations of HPMC and SLS were used utilizing 
factorial design as the study plan. Amount of HPMC is affecting to the viscosity of the 
system, which reflects to the milling efficiency. Particle size and polydispersity index (PDI) 
were compared between the bead sizes as well as among the different stabilizer 
concentrations. Stability of nanosuspensions was assessed in three different storage conditions 
during the time period of three weeks. 
2 Materials and methods 
2.1 Materials 
ODM-106, IUPAC name 3-(4-bromobenzyl)-7-fluoro-1-methylquinazoline-2,4(1H,3H)-dione 
(Orion, Espoo, Finland), an investigational poorly water soluble active pharmaceutical 
ingredient (API), was used as a model drug for wet-ball milling. HPMC (Pharmacoat 603) 
from Shin-Etsu Chemical (Tokyo, Japan) and SLS (Merck KGaA, Darmstadt, Germany) were 
used as the stabilizers. SLS was used as an electrostatic stabilizer and HPMC was used as a 
steric polymeric stabilizer. PVP and vitamin E TPGS were procured from Sigma, St. Louis, 
MO, USA. Methanol (HPLC grade, VWR International, Pennsylvania, USA), monobasic 
potassium phosphate (Sigma, St. Louis, MO, USA), sodium hydroxide (Sigma, St. Louis, 
MO, USA), hydrochloric acid (Merck KGaA, Darmstadt, Germany), and Polysorbate 80 
(Tween® 80, Fluka Chemika, Buch, Switzerland) were used for the characterization of 
nanosuspensions. In all the experiments ultrapurified Millipore® water (Millipore, Molsheim, 
France) was used. 
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2.2 Wettability of ODM-106 
The dynamic contact angle of the ODM-106 with water and with aqueous solutions of the 
surface active excipients (0.1% w/v) and suspending agents (1% w/v) was determined using 
DCAT 11 (DataPhysics Instruments GmbH, Filderstadt, Germany). The ODM-106 
micronized drug was attached to the rectangular microscopic slide partially covered with 
standard double-sided adhesive tape. The velocity of plate’s feed was 200 µm/s, the 
immersion depth was 10 mm. The measurements were run in triplicate. 
2.3 Wet-ball milling 
Nanosuspensions were prepared by the wet-ball milling technique. A custom central 
composite design was utilized to statistically investigate the interaction between three 
independent variables: (1) HPMC concentration (5 level numeric factor), (2) SLS 
concentration (3 level numeric factor), and (3) milling beads diameter (2 level category 
factor), on two dependent variables: drug particle size (nm) and PDI. Design matrices were 
comprised of 26 runs.  
Stabilizer solutions were made by dissolving HPMC (0.625 – 5.0 % w/w) and SLS (0.0625 – 
0.1875 % w/w) in water. The API (1.25 g), aqueous stabilizer solution (5 g) with different 
proportions of HPMC and SLS, and zirconium oxide milling beads (30 g, diameter 0.5 mm or 
1.0 mm) were placed into the milling vessel (vessel volume 20 mL) and dispersed. With the 
addition of API, final concentrations of HPMC were 0.5, 1, 2, 3 and 4 % w/w (level: -1.5, -1, 
0, +1, +2, respectively) and final SLS concentrations were 0.05, 0.1 and 0.2 % w/w (level: -1, 
0, +1, respectively) (Table 1). Amounts of the API, stabilizer solution and milling beads were 
determined based on preliminary studies and initial screening experiments. The milling speed 
and quantities of the beads were fixed and used to the recommended levels from the 
equipment supplier. The milling vessels were then inserted into the planetary ball mill 
(Pulverisette 7 Premium, Fritsch Co., Idar-Oberstein, Germany) and the grinding was 
performed at 1100 rpm. There were 10 milling cycles of 3 minutes and there was a 15 min 
break after each cycle to allow the system to cool down. These parameters were also 
determined in preliminary studies. After the milling process, nanosuspensions were collected 
and separated from the milling beads by pipetting from the vessel. Unless otherwise specified, 
all the concentrations refer to the mass of the substance with respect to the total content of 
suspension, w/w (API, water and stabilizers).  
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Table 1. Experimental runs according to the central composite design. 
Run HPMC % w/w SLS % w/w Milling beads diameter (mm) 
1 2 0.2 1.0 mm 
2 0.05 0.1 1.0 mm 
3 0.05 0.1 0.5 mm 
4 4 0.1 1.0 mm 
5 3 0.1 0.5 mm 
6 4 0.1 0.5 mm 
7 3 0.1 1.0 mm 
8 1 0.1 0.5 mm 
9 1 0.1 1.0 mm 
10 2 0.05 0.5 mm 
11 2 0.2 0.5 mm 
12 1 0.2 0.5 mm 
13 1 0.2 1.0 mm 
14 2 0.05 1.0 mm 
15 1 0.05 0.5 mm 
16 1 0.05 1.0 mm 
17 2 0.1 1.0 mm 
18 2 0.1 0.5 mm 
19 2 0.2 0.5 mm 
20 3 0.2 0.5 mm 
21 2 0.2 1.0 mm 
22 3 0.2 1.0 mm 
23 2 0.05 0.5 mm 
24 3 0.05 0.5 mm 
25 2 0.05 1.0 mm 
26 3 0.05 1.0 mm 
2.4 Particle size distribution 
The mean particle sizes and polydispersity indexes (PDIs) of the nanosuspensions were 
analyzed by photon correlation spectroscopy (PCS) with Malvern Zetasizer 3000HS (Malvern 
Instrument, Malvern, UK). PDI means the width of the particle size distribution. The lower 
the PDI value, the more monodisperse in size the particles are. If the PDI is higher than 0.7, 
the particles in suspensions are polydisperse. A part of the fresh nanosuspension was diluted 
with saturated solution containing ca. 0.1 % w/w of HPMC, in order to achieve a suitable 
concentration for the measurements by PCS. The nanosuspensions were sonicated for 4 min 
8 
 
before the size measurements. The analyses were performed with a dispersant refractive index 
of 1.33. The measurements were performed 3 times for each sample. 
2.5 Transmission electron microscopy (TEM) 
The selected suspensions were pipetted on formvar film-coated copper grids with mesh size of 
300 (Agar Scientific, Essex, UK) and dried at ambient temperature. The morphological 
evaluation of the particles was done using TEM (Jeol JEM-1400, Jeol Ltd., Tokyo, Japan). 
2.6 Solid state characterization 
To determine the polymorphic transformation(s) during wet milling, if any, differential 
scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) analyses were performed. 
Nanosuspension containing 0.1% of SLS and 2% of HPMC, centre point of all the studied 
stabilizer concentrations, was chosen for this evaluation and compared with the unmilled form 
of ODM-106. 
2.6.1 DSC 
Thermal properties of room temperature dried samples were analyzed with a DSC 823e 
(Mettler Toledo Inc., Columbus, USA). The samples were placed in sealed aluminium pans 
perforated in the lid. The temperature range for the measurements was from 0 to 200 ˚C with 
the heating rate of 10 ˚C/min. The measurements were performed under nitrogen flow of 50 
ml/min. Pure bulk drug, HPMC, and physical mixtures of the drugs and the stabilizers (in the 
same weight ratio as nanocrystals) were tested as controls. The data were analyzed with 
STARe software (Mettler Toledo, Columbus, USA). 
2.6.2  XRPD 
XRPD patterns were determined from dried nanomilled samples, pure drugs and physical 
mixtures of drugs and stabilizers by an X-ray diffractometer (Bruker AXS D8, Karlsruhe, 
Germany). The XRPD was performed in symmetrical reflection mode using Cu-Kα radiation 
with λ = 1.54 Å (40 kV and 40 mA). The sample was placed on a flat aluminium sample 
holder. Data were collected by scanning from 5˚ to 50˚ with 0.01˚ steps. 
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2.7 Stability testing 
Nanosuspensions were envisioned to be dried for final formulation development within a two 
weeks period. However, the physical stability of nanosuspensions was tested for a longer 
period of time,  up to three weeks, by monitoring particle size distribution to better understand 
the stabilization efficiency at different SLS concentrations (HPMC concentration was fixed at 
2%) under several temperature settings: refrigerated condition (4 ± 2 °C), ambient room 
temperature (25 °C), and 40 ± 2 °C. Samples were taken at the interval of 1 week and were 
diluted as per instructions for particle size distribution analysis after 30 seconds of vortex 
shaking of nanosuspension vials, followed by 1 min of sonication, and once more 30 seconds 
of additional vortexing.  
2.8 Statistical analysis 
Interactions between stabilizers’ concentration and milling beads diameters and their effects 
on particle sizes, were statistically studied using design of experiment approach (Design-
Expert ver. 11, Stat-Ease, Inc.). ANOVA test was performed to get information on significant 
parameters. The level of significance was fixed at p = 0.05. 
3 Results and discussion 
3.1 Contact angle of ODM-106 
One stabilizer can be enough for stabilizing drug nanocrystals (Liu et al., 2011), but often two 
stabilizers, typically a mixture of a polymer and a surfactant, are used in order to further 
improve the stabilization effect, which combines the advantages of both steric and 
electrostatic stabilizations. (Ghosh et al., 2013; Leung et al., 2014; Van Eerdenbrugh et al., 
2008). Excipients increasing drug wettability offer better stabilization of nanosuspensions 
(Cerdeira et al., 2010; Li et al., 2018). Wettability of a drug substance by a stabilizer solution 
is typically determined by measuring the contact angle. HPMC and PVP were selected as 
suspending agents, and SLS, Tween 80, and Vitamin E TPGS were chosen as surfactants to 
make different mixtures of stabilizer solutions. The average contact angle (CA) values are 
reported in the Table 2. The smaller the contact angle between drug and stabilizer the better 
the wettability. ODM-106 showed poor wettability properties in water considering a CA scale 
0-180˚, where 0˚ denotes completely wettable and 180˚ completely unwettable. At the 
selected concentrations, SLS and Tween 80 seemed to improve wettability more than TPGS. 
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PVP-SLS combination greatly reduced the CA and, therefore, was the first choice as 
stabilizing agent for nanomilling. However, compatibility studies between PVP and ODM-
106 revealed high degradation risks. PVP usually has hydroxyl and aldehyde groups in the 
terminal ends of the macromolecule, which underlie its redox reactivity (Amri and Roger, 
2020). Also, PVP typically contains peroxides as impurities and therefore it is often discarded 
from the early stages of formulation development based on the results of incompatibility 
studies (Wu et al., 2011). These incompatibility results indicated that other stabilizers like 
polyethylene glycol (Hemenway et al., 2015) and polyoxyethylene-polyoxypropylene block 
copolymer will also not be suitable since trace levels of peroxides, aldehydes and organic 
acids are also present in these, which are linked to instability of active ingredient 
(Wasylaschuk et al., 2007). It is well known that the degradation risk is higher in the liquid 
formulation such as nanosuspension, moreover, high energy involved in the wet milling 
process will increase the rate of the API degradation.  Therefore, HPMC was chosen as the 
suspending agent and SLS as the surface active excipient to form the most appropriate 
stabilizer solutions. 
 
Table 2. Summary of contact angle (CA) data of drug in water and aqueous 
suspending/surfactant solutions. 
Suspending 




- - 140 ± 3 
HPMC SLS 82 ± 2 
HPMC Tween 80 89 ± 1 
HPMC Vitamin E TPGS 97 ± 4 
PVP SLS 76 ± 1 
PVP Tween 80 86 ± 4 
PVP Vitamin E TPGS 122 ± 3 
3.2 Nanomilling 
3.2.1 Effect of milling time 
Milling time at constant milling speed is a direct measurement of energy input to the system 
(Peltonen, 2018; Singh et al., 2011). Given that required nanomilling energy is specific to 
drug crystals properties, there is no specific value applicable to all drugs. In general, longer 
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milling time is likely to support comminution because of higher energy input with increased 
numbers of collisions between drug particles and milling beads (Toziopoulou et al., 2017). 
However, longer milling time may also increase the temperature of the milling vessel, which 
in turn can cause crystal growth due to Ostwald ripening in the system, and may also lead to 
contamination from milling beads or vessel.  
The required milling time for ODM-106 was determined by dispersing bulk ODM-106 (1.25 
g) in 5 ml of aqueous stabilizer solution containing HPMC (125 mg; 10% relative to the drug 
amount) and SLS (6.25 mg; 0.5% relative to the drug amount) (Figure 1). Routinely, the 
mean diameters of bulk crystalline drug materials are tens of micrometers and the size 
distributions are broad (particle size distribution of ODM-106 micronized drug was d10 = 5.8, 
d50 = 17 and d90 = 80 µm). After milling for only 6 minutes (2 milling cycles, each of 3 min), 
the mean size of the drug was decreased dramatically below 1 µm. With increasing milling 
times, the sizes and the PDI were decreased further. The size-decreasing trend for the model 
drug was observed due to the long milling time that splits bigger particles into smaller ones 
and provides adequate time for the stabilizers to cover the drug surfaces. No significant 
reduction in particle sizes and size distributions were observed after further prolonging the 
milling times beyond 30 min of media milling (10 cycles).  
Particle size reduction with an increase in milling time can be attributed to the increase in the 
energy and shear forces produced due to impact between the grinding balls and the drug that 
provides high energy to break the microparticles to nanosized particles (Liu et al., 2011). 
Additional mechanical energy by prolonging milling could have a negative impact on the 
stability of the system by breaking the repulsive forces and causing aggregation of the small 
particles (Liu et al., 2011). Given that further continuation of milling was not beneficial, the 



























Figure 1. The effect of milling time on mean particle size (bars) and polydispersity index 
(circles). 
3.2.2 Effect of stabilizer concentration and bead size 
Particle size and PDI of nanosuspensions at different stabilizer concentrations and milling 
beads are presented in Figure 2. The measured PDI was in most cases close to or below 0.3, 
which is an indicator of good particle size uniformity (Patel et al., 2014).  
It is well established that increasing amount of steric stabilizer, such as HPMC, results in 
more efficient particle size reduction (Azad et al., 2016; Knieke et al., 2013; Peltonen and 
Hirvonen, 2010). Usually one stabilizer can be enough for stabilizing drug nanocrystals (Liu 
et al., 2011), but often two stabilizers, typically a mixture of a polymer like HPMC and an 
ionic surfactant like SLS are used in order to further improve the stabilization effect, which 
combines the advantages of both steric and electrostatic stabilizations (Ghosh et al., 2013; 
Leung et al., 2014; Van Eerdenbrugh et al., 2008).  
Stabilization due to electrostatic stabilizers alone is sensitive to pH, ionic strength, etc., as in 
drying. Therefore, combined stabilization effect is much needed where the objective is to 
develop a dry nanoformulation for oral dosing (Beirowski et al., 2011). After stabilizer 
selection based on the contact angle and compatibility data, optimal concentration needs to be 
decided for stabilizing the smaller sized particles and for maintaining the shelf-life stability of 




Figure 2. The effect of different HPMC and SLS concentrations on media milling using (a) 
0.5 mm and (b) 1 mm milling beads. Average particle sizes in bars and PDI values in 
symbols. 
In this study, we noticed that optimum proportions of HPMC and SLS were needed for 
maximum particle size reduction. As can be seen from Figure 2, the effect of HPMC on 
particle size reduction depended on the amounts of SLS. Nanomilling using 1 mm beads 
demonstrated decrease in particle size with the increase in HPMC concentration from 1% to 
2% at 0.05% and 0.1% of SLS concentrations (Figure 2(b)). Similar decrease in particle size 
was also observed using 0.5 mm beads at the lowest studied SLS concentration (0.05%).  
As the particles are becoming smaller during milling, their surface area as well as number 
concentration is increasing, leading to an increase in collision frequency and decrease in inter-
particle distances (Azad et al., 2016). Therefore, it is important to sufficiently protect particles 
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covering more surfaces and providing sufficient steric stabilization (Knieke et al., 2013; 
Peltonen and Hirvonen, 2010). With an  increase in HPMC concentration i.e., 1% to 3% (2 
mPa s to 5 mPa s, respectively at 20 ˚C in aqueous solution (Shin-Etsu, 2004)), the efficiency 
of particle size reduction of the milling process is reduced, which is probably because of an 
increase in viscosity of the suspension. In general, grinding efficiency increases with 
increased solids concentration and viscosity (Kwade, 1999), which is also consistent with the 
results for 1.0 mm beads at 1 and 2 % HPMC concentrations. However, if suspension 
viscosity is too high, the grinding efficiency drops due to a decrease of movement between 
the grinding media and the product suspension (Kwade, 1999).  
In comparison to 1 mm beads, 0.5 mm beads have a higher surface area and thus higher 
probability of contact with the API and thereby reducing particle size by impaction forces. 
However, smaller beads are more sensitive to viscosity changes since smaller and lighter 
beads do not have enough kinetic energy to break the particles in more viscous media 
(Peltonen, 2018) and, therefore, particle size reduction is not as effective anymore (Sepassi et 
al., 2007). Thus, increasing milling speed might be a way to achieve efficient comminution of 
drug particles in a highly viscous dispersion medium (Medarevic et al., 2018). At 0.2% 
concentration of SLS, the small difference between 0.5 and 1.0 mm beads might be because 
the minimal size has already been achieved at lower concentrations with 0.5 mm beads and 
further increase of SLS concentration does not reduce the particle size further. However, for 
1.0 mm beads, adding SLS still contributed to reaching smaller particle size, hence it came 
closer to the particle size achieved by using 0.5 mm beads. 
When HPMC concentration was increased to 4%, it was observed that the obtained 
suspension was very viscous (6 mPa s, 20 ˚C in aqueous solution), and after some days of 
storage at room temperature, it solidified in both 1.0 mm and 0.5 mm batches. Interestingly, 
lowering the HPMC concentration also resulted in the formation of very unstable suspensions, 
which had a strange morphology even right after the milling process, as depicted in Figure 3. 
Also, it was observed that only after a few days, there was a very distinct phase separation 
when the concentration of HPMC was 1% or lower with 1.0 mm beads, and 0.5% with 0.5 
mm beads. The reason behind this behaviour might be that at some concentration point, the 
amount of HPMC was not sufficient to prevent the beads from generating more energy by 
collisions and thereby heating the suspension over a certain threshold, above which the 
morphological changes were observed. With 0.5 mm beads, which most likely have less 
kinetic energy than 1.0 mm beads at the same milling conditions, this threshold occurs at 
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lower HPMC concentration and suspension viscosity, where the kinetic energy is still 
sufficient.  
Furthermore, HPMC is a polymer with lower critical solution temperature (LCST) between 75 
and 90 ˚C and, therefore, with increasing temperature it forms reversible gels via hydrophobic 
interactions occurring between the hydrophobic sections of the polymer chains (Marefat 
Seyedlar et al., 2014). It was expected to observe such sol to gel transitions in this study as 
well, due to the heat generated with high kinetic energy in less viscous solutions where 
HPMC concentration was below 1% for 1 mm beads and 0.5% for 0.5 mm beads. Also, the 
presence of water has a significant effect on the glass transition temperature (Tg) of a polymer 
(Perfetti et al., 2012). Perfetti et al. (2012) observed a decrease in Tg from 120 °C to 
approximately 70 °C, when the water content in HPMC (Pharmacoat 603) was increased from 
0 to 12%. Considering that the milling vessel felt unusually warm after the experiment with 
the lower HPMC concentration, it is possible that Tg was reached, which might be related to 
the observed effect on the consistency of the nanosuspensions. Nevertheless, to prove that 
with more certainty, more studies are required to further examine the effect of temperature 
associated behaviour of nanosuspensions stabilized by HPMC. 
 
Figure 3. Appearance of the suspensions in milling bowl immediately after milling. 
Compositions with (a) 0.1% SLS, 0.5% HPMC resembles a gel at both milling beads 
diameters and (b) compositions with 0.05% SLS, 1% HPMC resembles gel only with 1mm 
milling beads. Other compositions (c) and (d) with higher HPMC concentrations resulted in 
good nanosuspensions. Inner diameter of the milling bowl is 48 mm. 
SLS 0.1%, HPMC 0.5%, 0.5mmSLS 0.1%, HPMC 0.5%, 1mm
SLS 0.2%, HPMC 3%, 0.5mmSLS 0.2%, HPMC 3%, 1mmSLS 0.05%, HPMC 3%, 1mm SLS 0.05%, HPMC 3%, 0.5 mm 





The addition of SLS as an electrostatic stabilizer in combination with HPMC is well known to 
be beneficial for the stabilization effect (Knieke et al., 2013; Knieke et al., 2015; Parmentier 
et al., 2017; Peltonen, 2018). The stabilizing effect is due to the adsorption on particle 
surfaces and, thereby, formation of surfaces with a charge sufficient for stabilization 
(Peltonen and Hirvonen, 2010). Figure 2 shows a very similar phenomenon as was noticed 
with HPMC; with 1.0 mm beads, the particle size seemed to decrease with an increase in SLS 
concentration, whereas with 0.5 mm beads, there were no significant changes. It has been 
reported in literature that an increase in SLS content above a certain point does not further 
influence the particle size, because a minimum for the applied grinding operation has already 
been reached (Knieke et al., 2013). Although more experiments would be needed to claim that 
also in this case, this could also be the reason for the observation for 0.5 mm beads. 
3.2.3 Morphology of nanocrystals 
The SEM image of micronized API is presented in Figure 4(a). Before nanomilling, raw drug 
materials consisted of micron sized crystals. After wet milling, the ODM-106 crystals in the 
presence of the stabilizers were transformed into nanocrystals. The morphology of drug 
nanosuspension was observed using TEM (Fig. 4(b)). The angular surfaces of the drug 







Figure 4. Morphology of drug crystals. (a) SEM image of micronized bulk ODM-106 and (b) 
TEM image of ODM-106 nanocrystals made with 0.05% SLS and 2% HPMC using 0.5 mm 
beads. 
3.3 Crystalline state evaluation 
The DSC thermograms are shown in Figure 5. The extrapolated onset temperature was used 
to define the melting point (Tm). Pure drug showed a sharp endothermic melting peak at 161 
˚C and HPMC showed a broad endothermic peak in the range 40-100 ˚C. The endothermic 
peak of the physical mixture showed slight broadening, which was expected due to the 
solubility of drug with the polymeric stabilizer. Comparing the curves of physical mixtures 
and nanocrystal samples implies that no significant differences were found and ODM-106 
exists in crystalline form after the milling. In the DSC thermogram, a larger shift in the 
nanocrystals peaks to lower melting temperatures (157 ˚C) can be seen, which could be due to 
the smaller drug particle size, resulting in more solid state solubility of API in polymeric 
stabilizer. Melting transition, being a colligative property, decreases with the increase in 
solubility of drug in the polymer, HPMC in this case, and will depend on the amount of 
polymer present (Chokshi et al., 2005). Such decrease in melting transition after nanonization 
has also been reported previously (Gahoi et al., 2012; Liu et al., 2011; Teeranachaideekul et 























Figure 5. The DSC patterns of nanocrystals (SLS 0.1% and HPMC 2%), physical mixture, 
micronized bulk drug, SLS and HPMC. 
 
The X-ray diffractograms are shown in Figure 6. The diffraction pattern of micronized drug 
exhibited sharp peaks at 12˚, 14˚, 15˚, 17˚, 20˚, 22˚, 24˚ and 27˚ 2θ. The position of all 
characteristic ODM-106 peaks remained in the diffractograms of its physical mixtures with 
HPMC and SLS, and also in the nanocrystals. However, low peak intensities in 
nanoformulations were observed, owing to the smaller size of the drug and covering of the 
particles surface with the stabilizer that resulted in the broadening of the peaks and 
appearance of weak amorphous halo in the background instead of intense narrow peaks (Hecq 
et al., 2005). Combining the results of DSC and XRPD, it was established that the milling 
does not interfere with the crystallinity or polymorphic form of the drug compound. 
 
Figure 6. X-ray diffraction analyses of nanocrystals (SLS 0.1% and HPMC 2%), physical 
mixture, micronized bulk drug, SLS and HPMC. 
3.4 Physical stability of suspensions 
For testing the stability of the prepared nanosuspensions, three different formulations in 
triplicates were made with both beads sizes. Given that at 2% HPMC concentration both the 
milling beads sizes demonstrated efficient milling, the concentration of HPMC was fixed at 













2% and three different SLS concentrations were selected (0.05, 0.1 and 0.2%). All chosen 
formulations were stored in three different conditions: ambient temperature (25 °C), 4 °C and 
40 °C. Stability was assessed via particle size and PDI value measurements, where particle 
size increase and/or increase in PDI was interpreted as an indicator of physical instability 
(Ghosh et al., 2013; Knieke et al., 2015). At first, the effect of temperature was studied on 
nanosuspensions prepared using the centre point conditions (Figure 7). 
The stability study results of formulation prepared with 2% of HPMC and 0.1% of SLS using 
0.5 mm beads revealed that there was a significant increase in particle size after 7 days of 
storage at all temperature conditions, and after that no further significant changes in particle 
sizes were noticed (Figure 7(a)). The initial increase in particle size could be associated with 
relaxation of nanoparticles after high shear milling; since the energy inputs are very high 
during milling, the suspension is likely to be far away from equilibrium state after milling, 
and needs some time to achieve it (Deng et al., 2008). However, stability results from 
nanosuspensions prepared using 1 mm beads demonstrated no significant changes in particle 
sizes at all storage conditions (Figure 7(b)). PDI values for all batches remained below 0.5, 
which is considered as an index for good particle size uniformity for nanosuspensions 
(Mohammadi et al., 2011), meaning the stability was satisfactory from this point of view. 
However, there is quite a lot of fluctuation in particle sizes as well as in PDIs throughout the 
whole time period of observation seen in all the figures. That might be due to the nature of 
sample preparation and measurements; since only a small part of the suspension is taken for 
one analysis, it can hardly account for the state of the whole sample, although the results are 




Figure 7. Effect of various stability temperature conditions on the growth of ODM-106 
nanocrystals prepared with 2% HPMC and 0.1% SLS as a stabilizer. (a) Mean particle size 
using 0.5 mm beads, and (b) mean particle size using 1 mm beads. Particle sizes in bars and 























(a) 4 ˚C 25 ̊ C 40 ̊ C



























Figure 8. Effect of various concentrations of SLS (%) to inhibit the growth of ODM-106 
nanocrystals during stability study at 4 °C. (a) Mean particle size using 0.5 mm beads, and (b) 
mean particle size using 1 mm beads. HPMC concentration fixed at 2%. Particle sizes in bars 
and PDI values in symbols. 
Given the fact that least fluctuations in the size and PDI were noticed from samples stored in 
refrigerated conditions, the effect of SLS concentration on 3 weeks stability was studied only 
from those samples (4 ± 2 °C). In Figure 8(a) it can be seen that for 0.5 mm beads and SLS 
concentration of 0.1% there is some initial increase in particle size from day 0 to day 7 (p = 
0.017), after which no distinct trend was visible anymore in either of the storage conditions. 
For 1.0 mm beads and 0.1% or 0.05% SLS, on the other hand, the average particle size 
seemed to be decreasing throughout the observation period. A similar behaviour, however, 
has been reported by Deng et al. (2008), who noticed particle size reduction after initial 
increase, as well as a change in surface morphology throughout the testing period (Deng et al., 
2008). They recognized the observation to the process of reaching the equilibrium state by 
reorganization of the stabilizer molecules. After the high shear milling process, the system is 
far from the thermodynamic equilibrium and thus evolves to a new organized state. This 



















































Thereafter, the polymeric structure in the nanosuspension is relaxed spontaneously with an 
apparent size reduction and disassociation of clusters into individual particles. Ultimately, the 
nanosuspensions are aimed to transform into dried nanocrystals to make an oral solid dosage 
form. 
When the applied concentration of SLS was 0.2%, slight increase in the particle size was 
noticed with both the bead sizes. That could be due to the fact that the critical micelle 
concentration (CMC) might have been exceeded in this case. This could have a significant 
deleterious effect on physical stability of the suspension, since the presence of charged 
micelles could facilitate particle aggregation in the suspension (Richetti and Kékicheff, 1992). 
Furthermore, when SLS concentration is higher than CMC, the drug starts entering the 
micelles, but at the same time, it also starts precipitating from them. That results in the 
formation of solid drug particles without any stabilizers, where the Ostwald ripening can 
occur (Azad et al., 2016; Ghosh et al., 2011). The CMC value for SLS is 0.23% (Azad et al., 
2016; Knieke et al., 2013), which is lower than the concentration in this study, but it also has 
to be acknowledged that the presence of polymers in the solution can affect the CMC.  
Kumar et al. (2013) found out that an increase in the percentage of various PEG polymers led 
to an increase in CMC in cationic polymers (Kumar et al., 2013). Although the applied 
polymer as well as the surfactant were not the same in this experiment, CMC would have to 
be determined by an appropriate method to claim with certainty that CMC has really been 
exceeded. Furthermore, SLS in the nanosuspensions is not free in the solution, but is rather 
attached to the solid drug surfaces, which also indicates that the amount of SLS to reach CMC 
should be higher. Since the observed increase in particle size over time was not very drastic, 
exceeding CMC seems unlikely. 
4 Conclusion 
The present study aimed at investigating the impact of using different milling beads sizes in 
the wet-ball milling process on drug particle size when different stabilizer concentrations 
were used. It has been concluded that the effect of bead size on particle size is complex and 
highly dependent on the properties of the whole system, particularly the concentration of both 
the used stabilizers, i.e. HPMC as well as SLS. Although it has been observed that smaller 
bead size generally leads to smaller particle sizes, as expected from the literature, the 
complexity of the whole system needs to be considered. Especially the concentration of 
HPMC seemed to be of particular importance here, since it greatly affected the suspension 
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viscosity. Firstly, it has been seen that higher HPMC concentration and, thereby, more viscous 
suspension resulted in a smaller difference between the 0.5 mm and 1 mm milling beads 
under a given SLS concentration. Secondly, lowering HPMC concentration has been shown to 
have a significant effect not only on particle size, but also on the consistency of the 
suspensions, most probably due to the associated temperature changes during the process. 
Also in this case, the behaviour of suspensions differed between the two bead sizes. The 
suspensions tested on three-week stability at different storage conditions generally showed 
satisfactory physical stability, regardless of the storage temperature.  
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Table 1. Experimental runs according to the central composite design. 






Figure 1. The effect of milling time on mean particle size (bars) and polydispersity index 
(circles). 
Figure 2. The effect of different HPMC and SLS concentrations on media milling using (a) 
0.5 mm and (b) 1 mm milling beads. Average particle sizes in bars and PDI values in 
symbols. 
Figure 3. Appearance of the suspensions in milling bowl immediately after milling. 
Compositions with (a) 0.1% SLS, 0.5% HPMC resembles a gel at both milling beads diameter 
and (b) compositions with 0.05% SLS, 1% HPMC resembles gel at only 1mm milling bead. 
Other compositions (c) and (d) with higher HPMC concentrations resulted in good 
nanosuspension. Inner diameter of the milling bowl is 48 mm. 
Figure 4. Morphology of drug crystals. (a) SEM image of micronized bulk ODM-106 and (b) 
TEM image of ODM-106 nanocrystals made with 0.05% SLS and 2% HPMC using 0.5 mm 
beads. 
Figure 5. The DSC patterns of nanocrystals (SLS 0.1% and HPMC 2%), physical mixture, 
micronized bulk drug, SLS and HPMC. 
Figure 6. X-ray diffraction analyses of nanocrystals (SLS 0.1% and HPMC 2%), physical 
mixture, micronized bulk drug, SLS and HPMC. 
Figure 7. Effect of various stability temperature conditions on the growth of ODM-106 
nanocrystals prepared with 2% HPMC and 0.1% SLS as a stabilizer. (a) Mean particle size 
using 0.5 mm beads, and (b) mean particle size using 1 mm beads. Particle sizes in bars and 
PDI values in symbols. 
Figure 8. Effect of various concentrations of SLS (%) to inhibit the growth of ODM-106 
nanocrystals during stability study at 4 °C. (a) Mean particle size using 0.5 mm beads, and (b) 
mean particle size using 1 mm beads. HPMC concentration fixed at 2%. Particle sizes in bars 
and PDI values in symbols. 
 
